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(57) ABSTRACT 
The presently-disclosed subject matter includes methods for 
treating Alzheimer's disease in a Subject. The Subject can 
have Alzheimer's diseases, can be identified has being at risk 
for developing Alzheimer's disease, or both. The method can 
comprise administering a composition that includes a CD33 
inhibitor, which may include a CD33 antibody. In some 
embodiments the composition can further comprise at least 
one additional component useful for treating Alzheimer's 
disease. The presently-disclosed Subject matter also includes 
compositions and kits for treating Alzheimer's disease in a 
Subject. 
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1. 
METHOD, COMPOSITION, AND KIT USEFUL 
FORTREATMENT OF ALZHEMERS 
DISEASE 
RELATED APPLICATIONS 
This application claims priority from U.S. Provisional 
Patent Application No. 61/733,126, filed Dec. 4, 2012, the 
entire disclosure of which is incorporated herein by this ref 
CCC. 
GOVERNMENT SUPPORT 
This invention was made with government Support under 
Grant Nos. P01-AG03.0128, P30-AG028383, and P20 
GM103436 awarded by the National Institutes of Health. The 
government has certain rights in the invention. 
TECHNICAL FIELD 
The presently-disclosed subject matter relates to the treat 
ment of a subject having or identified as being at risk for 
developing Alzheimer's disease. In particular, the presently 
disclosed subject matter relates to methods and compositions 
for treating Alzheimer's disease by reducing functional CD33 
in a Subject. 
INTRODUCTION 
Recent genome-wide association studies (GWASs) have 
identified a set of single nucleotide polymorphisms (SNPs) 
that are associated with Alzheimer's disease (AD) risk. One 
of the AD-associated SNPs, rs3865444, is in the proximal 
promoter of CD33. CD33 is a member of the sialic acid 
binding Ig-like lectin (SIGLEC) family of receptors 
However, there has been limited progress in elucidating the 
mechanisms of action underlying such SNPs. This difficulty 
can be attributed to variability in human gene expression due 
to diversity in genetics and environment, including diet and 
drug exposure. The difficulty can also be attributed to the fact 
that the brain contains heterogeneous cell types, and control 
ling for variation in the proportion of cell types between 
samples is challenging. Lastly, AD-associated SNPs from 
GWAS are not typically functional, but rather are in linkage 
disequilibrium (LD) with functional SNP(s), which intro 
duces variability. 
Elucidating the mechanism of action of these SNPs could 
potentially be beneficial for identifying novel Alzheimer's 
disease pathways. Indeed, genetic variation that modulates 
disease risk could be considered to biologically define rate 
limiting steps in Alzheimer's disease pathways, and, as such, 
lead to robust new pharmacologic targets. For example, an 
SNP with modest biological actions may reduce Alzheimer's 
disease risk modestly, whereas a drug that acts strongly at the 
same target may have a large effect on Alzheimer's disease 
risk reduction. Elucidating the mechanism of action of AD 
associated SNP may therefore lead to the development of 
treatments for Alzheimer's disease. 
Hence, there remains a need to elucidate the mechanism of 
action of AD-associated SNPs. There also remains a need to 
develop novel compositions and methods for treating Alzhe 
imer's disease that are based on information elucidated form 
particular AD-associated SNPs. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 includes CD33 immunohistochemistry images in 
human brain showing CD33-immunopositive cell profiles 
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(arrows) that have a morphology consistent with microglia in 
both Alzheimer's disease (AD) and non-AD samples (A, B); 
and also includes immunofluorescence images used to help 
distinguish CD33-immunopositive cell types, where (C-H) 
show the same microscope fields and show sections immun 
ostained for CD33 and counterstained for IBA-1 (a micro 
glial/macrophage lineage marker) or GFAP (an astrocyte lin 
eage marker). Sections were from Superior/middle temporal 
gyri of subjects with AD pathology (A, C-H) or without (B) 
AD pathology. Ctrl, Control. Scale bar: a, b, 50 um; c-h, 20 
lm. 
FIG.2 includes charts of CD33 isoform expression relative 
to Alzheimer's disease status, showing (A) CD33 expression 
correlated with microglial gene expression (presented as geo 
metric mean of CD11b and AIF-1, r=0.64), (B) association 
between CD33 and Alzheimer's disease status visualized by 
considering the ratio of CD33 to the geometric mean of the 
microglial reference genes, (C) D2-CD33 correlated with 
CD33 expression (r=0.88, 0.67, and 0.51 for the AA, CA, 
and CC genotypes, respectively), and (D) the percentage of 
CD33 expressed as D2-CD33 associated with the rs3865444 genotype (p=1.2x10'). 
FIG. 3 includes a schematic showing the mechanisms for 
CD33 and TREM2 in microglial activation, where sialic acid 
binding to CD33 results in activation of SHP1 phosphatase 
that inhibits immune cell activation, the D2-CD33 isoform 
lacks the exon that encodes the apparent sialic acid binding 
domain, and a ligand binds TREM2 that signals through 
DAP12 to activate the tyrosine kinase Syk, resulting in micro 
glial activation. 
FIG. 4 includes a schematic showing the gene structure for 
CD33. 
FIG. 5 includes charts of Int1-CD33 expression relative to 
Alzheimer's disease status, showing (A) Int1-CD33 expres 
sion correlated with CD33 expression, (B) the percentage of 
CD33 expressed as Int1-CD33 associated with the rs3865444 
genotype, (C) total non-functional CD33 correlated with 
CD33 expression, and (D) the percentage of CD33 expressed 
as non-functional CD33 associated with the rs3865444 geno 
type. 
DESCRIPTION OF EXEMPLARY 
EMBODIMENTS 
The details of one or more embodiments of the presently 
disclosed subject matter are set forth in this document. Modi 
fications to embodiments described in this document, and 
other embodiments, will be evident to those of ordinary skill 
in the art after a study of the information provided in this 
document. The information provided in this document, and 
particularly the specific details of the described exemplary 
embodiments, is provided primarily for clearness of under 
standing and no unnecessary limitations are to be understood 
therefrom. In case of conflict, the specification of this docu 
ment, including definitions, will control. 
Some of the polynucleotides and polypeptides identified 
herein include sequence and other information in the GEN 
BANKR/GENPEPTOR database, which sequence and other 
information is expressly incorporated by reference. Unless 
otherwise indicated or apparent, the references to the GEN 
BANKOR/GENPEPTOR) database are references to the most 
recent version of the database as of the filing date of this 
Application. 
The presently-disclosed subject matter includes methods, 
compositions, and kits useful for the treatment of Alzheimer's 
disease (AD) in a Subject. In some embodiment, the Subject 
has Alzheimer's disease. In some embodiments, the Subject is 
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identified as being at risk for developing Alzheimer's disease. 
As such, treatment of Alzheimer's disease is not limited to 
treatment of subjects who have already been diagnosed with 
Alzheimer's disease, but is inclusive of the treatment of sub 
jects who are identified as having an increased risk of Alzhe 
imer's disease as compared to the general population. The 
phrase “increased risk” is used herein to refer to those sub jects whose likelihood of developinga Alzheimer's disease in 
their lifetime is increased, as compared to a normal Subject. 
Furthermore, the Subject can be a human Subject or a non 
human Subject. 
In some embodiments, the Subject is identified has having 
a single nucleotide polymorphism associated with risk of 
developing Alzheimer's disease. In this regard, certain 
mechanisms identified by these SNPs constitute “bottle 
necks' in Alzheimer's disease pathways. These bottlenecks 
can biologically define rate-limiting steps in Alzheimer's dis 
ease pathways, and, as such, can constitute targets for treat 
ment. For example, a SNP may reduce Alzheimer's disease 
risk modestly (e.g., 10%), but a drug that acts strongly at the 
same target may have a more robust (e.g., 10-50%) effect on 
Alzheimer's disease risk and gene function. 
In some embodiments, the SNP is the CD33 polymor 
phism, rs3865444, rs3865444 (rs444), a SNP near CD33, 
appears to be AD-associated, as shown in cohorts totaling 
more than 48,000 individuals (odds ratio=0.89, p=10). The 
present inventors identified the effect of rS444 on CD33 as 
well as different CD33 isoforms expressed in human brain. In 
certain subjects, a CD33 isoform containing all seven CD33 
exons can be relatively common, as can be nonfunctional 
CD33 isoforms, such as those lacking exon 2 (D2-CD33) or 
those retaining intron 1 (Int1-CD33). 
Thus, the present-disclosed subject matter provides an 
understanding of how Alzheimer's disease risk can be modu 
lated by genetic factors that influence microglial activation. 
Increased Alzheimer's disease risk has been associated with 
apparent inactivating mutations in the microglial activator 
TREM2, and TREM2 acts via DAP12 to activate Syk medi 
ated tyrosine phosphorylation to promote microglial phago 
cytosis (FIG. 3). The present inventors found that 
rs3865444A is associated with lower overall CD33 expres 
sion as well as exclusion of CD33 exon 2 and possibly other 
nonfunctional CD33 (e.g., Int1-CD33). 
In this regard, sialic acids activate CD33 to stimulate 
SHP1/SHP2 tyrosine phosphatases, resulting in inhibition of 
phagocytosis (FIG. 3). Because D2-CD33 lacks the IgV 
domain that is predicted to mediate sialic acid binding, 
D2-CD33 likely encodes a nonfunctional protein. Consistent 
with this, phagocytosis as measured by AB uptake has been 
found to be inhibited when BV2 cells are transfected with 
CD33, but not CD33 lacking the IgV domain. Hence, 
D2-CD33 likely represents a loss of CD33 function. There 
fore, it appears that TREM2 and CD33 act in opposing direc 
tions to modulate tyrosine phosphorylation and, thereby, 
microglial activation and AD risk. Alleles that inhibit TREM2 
function may increase Alzheimer's disease risk, whereas alle 
les that inhibit CD33 function may reduce Alzheimer's dis 
ease risk. 
Thus, the presently-disclosed subject matter relates to pro 
tective SNP alleles as well as Alzheimer's disease treatment 
methods and compositions that are based on the same. In 
certain subjects the AD-protectivers444A allele is associated 
with an about 10% per allele increase in the expression of 
CD33 lacking exon 2 (D2-CD33). Certain embodiments of 
the presently-disclosed subject matter relate to methods and 
compositions for treating Alzheimer's disease by reducing 
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functional CD33 and/or by reducing a ratio of functional 
CD33 to nonfunctional CD33. 
As used herein, the terms “treatment' or “treating are 
inclusive of prophylactic treatment and therapeutic treatment. 
As such, the terms treatment and treating include: preventing 
the disease from occurring in a Subject who may be predis 
posed to the disease but who has not yet been diagnosed as 
having it; inhibiting the disease, including arresting the pro 
gression or development of the disease; reducing the severity 
of the disease; ameliorating or relieving the symptoms of the 
disease; causing regression of disease; curing the disease; 
and/or stabilizing the disease. This term includes active treat 
ment, that is, treatment directed specifically toward the 
improvement of a disease, pathological condition, or disor 
der, and also includes causal treatment, that is, treatment 
directed toward removal of the cause of the associated dis 
ease, pathological condition, or disorder. In addition, this 
term includes preventative treatment, that is, treatment 
directed to minimizing or partially or completely inhibiting 
the development of the associated disease, pathological con 
dition, or disorder. 
In some embodiments, the method includes administering 
a composition for reducing functional CD33 in the subject, 
wherein the subject has Alzheimer's disease or is identified as 
being at risk for developing Alzheimer's disease. In some 
embodiments, the method includes administering a compo 
sition for reducing functional CD33 in the subject, wherein 
the Subject is identified as having a single nucleotide poly 
morphism associated with risk of Alzheimer's disease, e.g., 
rs3865444, rs12459419, or combinations thereof. 
The term “administering” refers to any method of provid 
ing a composition and/or pharmaceutical composition 
thereof to a subject. Such methods are well known to those 
skilled in the art and include, but are not limited to, oral 
administration, transdermal administration, administration 
by inhalation, nasal administration, topical administration, 
intravaginal administration, ophthalmic administration, 
intraaural administration, intracerebral administration, rectal 
administration, and parenteral administration, including 
injectable Such as intravenous administration, intra-arterial 
administration, intramuscular administration, Subcutaneous 
administration, intravitreous administration, intracameral 
(into anterior chamber) administration, Subretinal adminis 
tration, Sub-Tenon's administration, peribulbar administra 
tion, administration via topical eye drops, and the like. 
Administration can be continuous or intermittent. In various 
aspects, a preparation can be administered therapeutically; 
that is, administered to treat an existing disease or condition (e.g., exposure to OP compounds). In further various aspects, 
a preparation can be administered prophylactically; that is, 
administered for prevention of a disease or condition. 
In some embodiments, the composition administered can 
include a CD33 inhibitor. The CD33 inhibitor can be selected, 
for example, from a polypeptide inhibitor (including oligo 
nucleotide inhibitor), a small molecule inhibitor, an siRNA 
inhibitor, an antibody, an aptamer, a dominant negative plas 
mid or vector inhibitor, and combinations thereof. 
In this regard, the term “inhibit or the like does not nec 
essarily refer to the ability to completely inactivate all target 
biological activity in all cases. Rather, the skilled artisan will 
understand that the term “inhibit” refers to a decrease bio 
logical activity of a target, such as a decreasing expression of 
CD33 and/or functional CD33. This can occur by various 
mechanisms, including, but not limited to, altering the struc 
ture of a protein so that its intended function is limited or 
eliminated in in a biochemical pathway, blocking particular 
binding sites in a biological pathway, or the like. Such 
US 9,066,928 B1 
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decrease in biological activity (i.e., inhibition) can be deter 
mined relative to a control, wherein an inhibitor is not admin 
istered and/or placed in contact with the target. For example, 
in some embodiments, a decrease in activity relative to a 
control can be about a 1,2,3,4,5,6,7,8,9, 10, 11, 12, 13, 14, 
15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 
32,33,34, 35,36, 37,38,39, 40, 41, 42, 43,44, 45,46, 47, 48, 
49, 50, 51, 52,53,54, 55,56, 57,58, 59, 60, 61, 62,63, 64, 65, 
66, 67,68, 69,70, 71, 72,73,74, 75,76, 77,78, 79,80, 81,82, 
83, 84,85, 86, 87, 88, 89,90,91, 92,93, 94.95, 96, 97,98,99, 
or 100% decrease. The term “inhibitor refers to a compound 
of composition that inactivates or decreases the biological 
activity, such as CD33 inhibitors that inactivate or decrease 
the biological activity of CD33. 
In specific embodiments the composition administered can 
include a CD33 inhibitor that includes an antibody, wherein 
the antibody is a CD33 antibody. A non-limiting example of 
a CD33 antibody that could be used in connection with the 
presently-disclosed subject matter is lintuZumab. Another 
exemplary CD33 antibody can include P67.6. In some 
embodiments the CD33 inhibitor can include two or more 
different antibodies, some or all of which can be CD33 anti 
bodies. In some embodiments wherein the subject is admin 
istered a CD33 inhibitor, such as a CD33 antibody, the subject 
is not being treated for a cancer. 
Despite the various approaches, in some embodiments the 
administered composition includes humanized monoclonal 
antibodies against CD33, which have been developed for 
treatment of acute myeloid leukemia (AML). Antibodies 
(e.g., monoclonal antibodies targeting CD33) that can be used 
in conjunction with the present compositions, methods, and 
kits include “naked' antibodies, such as Lintuzumab, which 
is merely an antibody. Alternatively or additionally, the pro 
vided antibodies in certain embodiments can be conjugated to 
another biologically active agent, Such as the conjugated 
compound Gemtuzumab ozogamicin. Antibodies such as 
“LintuZumab' show specificity and target engagement in the 
periphery as well as a safety profile marked by minimal side 
effects. As CD33 antagonists, CD33 antibodies including 
Lintuzumab down-regulate CD33 from the cell surface in 
Vivo and in vitro. Hence, antibodies Such as LintuZumab 
represent immunoreagents with specificity and peripheral 
efficacy in target engagement, an acceptable safety profile, 
and demonstrated ability to antagonize CD33. 
In some embodiments, the method includes administering 
a CD33 inhibitor, which can itself include a CD33 antibody, 
and further includes administering a composition including at 
least one component useful for treating Alzheimer's disease. 
In some embodiments, the method includes administering a 
composition including a CD33 inhibitor and/or a CD33 anti 
body, and further including another component useful for 
treating Alzheimer's disease. Examples of Such components 
include, but are not limited to, Razadyne R (galantamine), 
Exelon R (rivastigmine), Aricept(R) (donepezil), CognexcR) 
(tacrine), and Namenda(R) (memantine). Exemplary compo 
nents use for treating Alzheimer's disease also can include 
vitamin E. 
Further still, other exemplary components for treating 
(e.g., ameliorating the symptoms of) Alzheimer's disease, 
and which can be administer in conjunction with a CD33 
inhibitor, include antidepressants, such as Celexa R. (citalo 
pram), ProzacR) (fluoxetine), Paxil.R (paroxetine), and 
Zoloft(R) (sertraline), anxiolytics, such as Ativan R. 
(lorazepam) and SeraXR (oxazepam), antipsychotic medica 
tions, such as Abilify(R) (aripiprazole), Haldol R (haloperidol), 
ZyprexaR (olanzapine), clozapine, risperidone, quetiapine, 
and Ziprasidone, anti-anxiety medications, such as benzodi 
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azepines (e.g., Valium(R) (diazepam) or Ativan R (lorazepam)) 
and non-benzodiazepines (e.g., Buspar R (buspirone)). 
In some embodiments, a method for treating Alzheimer's 
disease in a subject is provided that comprises administering 
a composition for reducing functional CD33, and further 
comprises administering another treatment for Alzheimer's 
disease. The subject can have and/or be identified as being at 
risk for developing Alzheimer's disease. The other treatment 
can include any of the compositions described herein. Exem 
plary treatments for Alzheimer's disease can also include 
hormone replacement therapy, sensory therapies, other thera 
pies, such as coenzyme Q10, coral calcium, huperzine A, and 
omega-3 fatty acids. 
In some embodiments of the present methods, the admin 
istered composition increases a ratio of nonfunctional CD33 
to functional CD33 in the subject. In some embodiments the 
compositions Sustain approximately the same level of func 
tional CD33 and activate (i.e., increases the level of) nonfunc 
tional CD33. In some embodiments the compositions reduce 
a level of functional CD33 and sustain approximately the 
same level of nonfunctional CD33. Further still, in some 
embodiments the compositions both reduce a level of (i.e., 
inhibit) functional CD33 and activate nonfunctional CD33. 
Nonfunctional CD33 refers to any CD33 that includes a 
mutation that alters, inhibits, or otherwise compromises the 
normal biological activity of CD33. This includes CD33 hav 
ing one or more deleterious SNPs. Nonfunctional CD33 also 
includes some fragments of functional CD33. Exemplary 
nonfunctional CD33 includes CD33 lacking exon 2 (D2 
CD33), CD33 retaining intron 1 (Int1-CD33), and the like. 
Accordingly, in Some embodiments of the present methods 
the compositions can increase a ratio of nonfunctional CD33. 
which can include D2-CD33, Int1-CD33, or combinations 
thereof, to functional CD33 in the subject. 
In some embodiments the subject that is being treated for 
Alzheimer's disease is not being further treated for cancer. 
Therefore, in some embodiments, the subject has not been 
diagnosed as having cancer and/or has not been identified as 
having a risk for developing cancer. In specific embodiments 
the Subject does not have, has not been diagnosed as having, 
and/or has not been identified as being at risk for developing 
acute myeloid leukemia (AML). In this regard, in some 
embodiments the present methods are performed only for the 
purpose of treating Alzheimer's disease. 
The presently-disclosed subject matter further includes a 
composition comprising a CD33 inhibitor and at least one 
additional component useful for treating Alzheimer's dis 
ease. As described herein, the CD33 inhibitor can include a 
polypeptide inhibitor, a small molecule inhibitor, an siRNA 
inhibitor, an antibody, an aptamer, a dominant negative plas 
mid or vector inhibitor, and combinations thereof. Further 
more, the CD33 inhibitor can include a CD33 antibody, such 
as lintuzumab, P67.7, or combinations thereof. Also as dis 
cussed herein, the at least one additional component useful 
for treating Alzheimer's disease can include, but is not limited 
to, galantamine, rivastigmine, donepezil, tacrine, memantine, 
Vitamin E, and combinations thereof. 
Embodiments of the present compositions are capable of 
increasing a ratio of nonfunctional CD33 to functional CD33 
in a Subject. Alternatively or additionally, exemplary compo 
sitions can also be capable of activating nonfunctional CD33 
in a subject, such as, but not limited to, D2-CD33 and/or 
Int1-CD33. 
Additionally, the presently-disclosed subject matter 
includes pharmaceutical compositions. Exemplary pharma 
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ceutical compositions can comprise any of the compositions 
described herein as well as a pharmaceutically acceptable 
carrier. 
The term “pharmaceutically acceptable carrier refers to 
sterile aqueous or nonaqueous solutions, dispersions, Suspen 
sions, emulsions, or nanoparticle delivery systems, as well as 
sterile powders for reconstitution into sterile injectable solu 
tions or dispersions just prior to use. Proper fluidity can be 
maintained, for example, by the use of coating materials such 
as lecithin, by the maintenance of the required particle size in 
the case of dispersions and by the use of Surfactants. These 
compositions can also contain adjuvants such as preserva 
tives, wetting agents, emulsifying agents and dispersing 
agents. Prevention of the action of microorganisms can be 
ensured by the inclusion of various antibacterial and antifun 
gal agents such as paraben, chlorobutanol, phenol, Sorbic acid 
and the like. It can also be desirable to include isotonic agents 
Such as Sugars, Sodium chloride and the like. Prolonged 
absorption of the injectable pharmaceutical form can be 
brought about by the inclusion of agents, such as aluminum 
monostearate and gelatin, which delay absorption. Injectable 
depot forms are made by forming microencapsule matrices of 
the drug in biodegradable polymers such as polylactide 
polyglycolide, poly(orthoesters) and poly(anhydrides). 
Depending upon the ratio of drug to polymer and the nature of 
the particular polymer employed, the rate of drug release can 
be controlled. Depot injectable formulations are also pre 
pared by entrapping the drug in liposomes or microemulsions 
which are compatible with body tissues. The injectable for 
mulations can be sterilized, for example, by filtration through 
a bacterial-retaining filter or by incorporating sterilizing 
agents in the form of sterile solid compositions which can be 
dissolved or dispersed in sterile water or other sterile inject 
able media just prior to use. Suitable inert carriers can include 
Sugars such as lactose. 
Suitable formulations include aqueous and non-aqueous 
sterile injection Solutions that can contain antioxidants, buff 
ers, bacteriostats, bactericidal antibiotics and Solutes that ren 
der the formulation isotonic with the bodily fluids of the 
intended recipient; and aqueous and non-aqueous sterile Sus 
pensions, which can include Suspending agents and thicken 
ing agents. 
The compositions can take Such forms as Suspensions, 
Solutions or emulsions in oily or aqueous vehicles, and can 
contain formulatory agents such as Suspending, stabilizing 
and/or dispersing agents. Alternatively, the active ingredient 
can be in powderform for constitution with a suitable vehicle, 
e.g., sterile pyrogen-free water, before use. 
The formulations can be presented in unit-dose or multi 
dose containers, for example sealed ampoules and vials, and 
can be stored in a frozen or freeze-dried (lyophilized) condi 
tion requiring only the addition of sterile liquid carrier imme 
diately prior to use. 
For oral administration, the compositions can take the form 
of for example, tablets or capsules prepared by a conven 
tional technique with pharmaceutically acceptable excipients 
Such as binding agents (e.g., pregelatinized maize starch, 
polyvinylpyrrolidone or hydroxypropyl methylcellulose): 
fillers (e.g., lactose, microcrystalline cellulose or calcium 
hydrogen phosphate); lubricants (e.g., magnesium Stearate, 
talc or silica); disintegrants (e.g., potato starch or sodium 
starch glycollate); or wetting agents (e.g., sodium lauryl Sul 
phate). The tablets can be coated by methods known in the art. 
Liquid preparations for oral administration can take the 
form of for example, Solutions, syrups or Suspensions, or 
they can be presented as a dry product for constitution with 
water or other suitable vehicle before use. Such liquid prepa 
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rations can be prepared by conventional techniques with 
pharmaceutically acceptable additives Such as Suspending 
agents (e.g., Sorbitol syrup, cellulose derivatives or hydroge 
nated edible fats); emulsifying agents (e.g. lecithin or acacia); 
non-aqueous vehicles (e.g., almond oil, oily esters, ethyl alco 
hol or fractionated vegetable oils); and preservatives (e.g., 
methyl or propyl-p-hydroxybenzoates or sorbic acid). The 
preparations can also contain buffer salts, flavoring, coloring 
and Sweetening agents as appropriate. Preparations for oral 
administration can be suitably formulated to give controlled 
release of the active compound. Forbuccal administration the 
compositions can take the form of tablets or lozenges formu 
lated in conventional manner. 
The presently-disclosed subject matter further includes a 
kit comprising a CD33 inhibitor, and at least one additional 
component useful for treating Alzheimer's disease. In some 
embodiments the kit comprises a CD33 inhibitor that 
includes an antibody, and at least one additional component 
useful for treating Alzheimer's disease. 
In some embodiments, kits can further include a device for 
administering the CD33 inhibitor and/or a device for admin 
istering the at least one additional component. The kit can 
comprise one device for administering the CD33 inhibitor 
and the additional component, or may comprise one device 
for each of the CD33 inhibitor and the additional component. 
The ordinary artisan will appreciate certain devices that can 
be utilized in conjunction with the present kits. For instance, 
injectable CD33 inhibitors, additional components, or both 
can be administered by a device that includes, but is not 
limited to, a syringe, a hypodermic needle, a catheter, or the 
like. 
Further still, the presently-disclosed subject matter relates 
to novel methods for elucidating the mechanism of particular 
SNPs. In some embodiments the methods comprise analyz 
ing quantitative gene expression as a function of splice vari 
ants and/or of cell-type variation among biological samples, 
Such as brain samples. By looking at quantitative gene expres 
sion in this relative manner, previous difficulties associated 
with characterizing the function of particular SNPs can be 
avoided or minimized. 
Such difficulties included the inability to evaluate the 
effects of particular gene expression due to the inherent vari 
ability in gene expression due to genetic and environmental 
conditions. Difficulties also included the inability to control 
the relatively types and concentrations of cells between dif 
ferent biological samples, which can include heterogeneous 
cell types. Thus, the present methods of analyzing quantita 
tive gene expression as a function of splice variants and/or 
analyzing quantitative gene expression as a function of cell 
type variation among biological samples, can avoid certain 
inherent and possibly ambiguous variations that were present 
in previous methods. 
In particular embodiments, as described herein, the present 
methods include a combination of qPCR assays specific to 
individual CD33 isoforms, controlling for microglial content 
in Samples, and/or recognizing that the functional polymor 
phism is linked with the Alzheimer's disease SNP (rs444). 
This method allowed the present inventors to elucidate the 
mechanism associated with various SNPs, including rS444. 
This method can be extended to elucidate the mechanism 
associated with other SNPs that are associated with Alzhe 
imer's disease. The present methods can also be extended to 
elucidate the mechanism associated with SNPs that are not 
associated with Alzheimer's disease. 
The presently-disclosed subject matter is further illustrated 
by the following specific but non-limiting examples. Some of 
the following examples are prophetic, notwithstanding the 
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numerical values, results and/or data referred to and con 
tained in the examples. Additionally, the following examples 
may include compilations of data that are representative of 
data gathered at various times during the course of develop 
ment and experimentation related to the present invention. 
EXAMPLES 
Example 1 
This Example describes procedures used to elucidate the 
mechanisms of the AD risk allele, rs3865444, and CD33. In 
particular, this Example demonstrates that CD33 expression 
is primarily microglial, that CD33 expression is increased in 
AD, and that the AD-protective rs3865444A allele acts via its 
proxy, rs12459419T, to increase the proportion of CD33 
(functional CD33) expressed as nonfunctional CD33 (e.g., 
D2-CD33). This Example thus identifies a novel mechanism 
for the protective allele of CD33 as well as potential treat 
ments that include CD33 modulation in subjects having and/ 
or at risk for developing AD. 
De-identified human brain specimens were provided by the 
University of Kentucky Alzheimer's Disease (AD) Center 
Neuropathology Core (Lexington, Ky.). Samples were from 
30 women (14 non-AD and 16 AD) and 25 men (13 non-AD 
and 12 AD). AD and non-AD designations were by consensus 
conference, with disease being defined based on dementia 
and AD neuropathology, i.e., neuritic plaques and neurofibril 
lary tangles. RNA and DNA were prepared from these 
samples. 
To perform CD33 immunostaining paraffin-embedded tis 
sue sections were cut at 5um, followed by antigen retrieval in 
citrate buffer, pH 6.0, using a pressure cooker (3 min). Sec 
tions were immersed in 5% goat serum in Tris-buffered 
saline, followed by an overnight incubation in anti-CD33 
(clone PWS44; 1:100 dilution; Leica). After thorough rinsing 
in Tris-buffered saline, sections were incubated in biotiny 
lated secondary antibody for 1 h, rinsed, incubated in ABC 
reagent (Vector Laboratories, Burlingame, Calif.) for 1 h, 
developed in Nova Red chromagen (Vector Laboratories), 
and counterstained with Mayer's hematoxylin. For immun 
ofluorescence, sections were treated similarly. Sections were 
then labeled with CD33 antibody (1:100), IBA-1 (rabbit poly 
clonal, 1:1000; Wako Chemicals, Richmond, Va.), and/or 
GFAP (rabbit polyclonal. 1:10,000; Dako, Carpinteria, 
Calif.), rinsed, and detected with labeled secondary antibod 
ies (antirabbit DyLight 488-labeled anti-rabbit, 1:500; Jack 
son Laboratories, Bar Harbor, Me., or Texas Red labeled 
anti-mouse, 1:500; Jackson Laboratories). Autofluorescence 
eliminator reagent (Millipore BioScience Research Reagents, 
Billerica, Mass.) was used to block autofluorescence. 
To identify CD33 splice variants in human brain, screening 
for CD33 splice variants was performed on a pool of four 
cDNA samples representing AD and non-AD individuals and 
varying rs3865444 genotypes. Nested PCR was used to 
amplify CD33 exons 1-7A and exons 1-7B in separate reac 
tions. An initial 20 cycles of PCR (Platinum Taq; Invitrogen, 
Carlsbad, Calif.) was performed by using forward primer 
5'-CTCAGACATGCCGC TGCT-3' (SEQ ID NO: 1) corre 
sponding to exon 1 and reverse primers 5'-TTCAATGGC 
CATCATCTCCT-3' (SEQ ID NO: 2) and 5'-CATCCCAT 
GAAAGTTGAGGG-3 (SEQ ID NO:3), corresponding to 
exons 7A and 7B, respectively. The PCR product was then 
diluted 1:25 and subjected to 30 cycles of amplification using 
forward primer 5'-TACTGCTGCCCCTGCTGT-3' (SEQ ID 
NO: 4) from exon 1 and 5'-TGGCCATCATCTCCTGATCT 
3' (SEQID NO:5) and 5'-AATGCAGCTCCTCATCCATC-3' 
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(SEQID NO: 6) corresponding to exons 7A and 7B, respec 
tively. PCR consisted of an initial 3-min 94° incubation, 
followed by cycles of denaturation at 94 for 15 s, annealing 
at 60° for 15s, and extension at 72° for 2 min (Veriti 96-Well 
Thermal Cycler: Invitrogen). PCR was conducted using 1 uM 
the indicated primers (1 uM) and -0.1 g of cDNA template. 
After PCR, samples were incubated at 72° for 30 min and then 
cloned into pcDNA2.1 according to the instructions of the 
manufacturer (TA-Cloning Kit; Invitrogen). Twenty-five ran 
dom clones were picked from each group amplification reac 
tion (exons 1-7A, exons 1-7B) and sequenced by using M13 
forward and reverse primers. In addition to common 
D2-CD33, one to two clones had both exons 7A and 7B, 
skipped other exons, or retained intron 1 (Int1-CD33). 
Quantitative PCR (qPCR) was used to quantify expression 
of total CD33 (forward, 5'-TGTTCCACAGAACCCAA 
CAA-3'(SEQ ID NO: 7); reverse, 5'-GGCTGTAACAC 
CAGCTCCTC-3' (SEQID NO: 8)) primers corresponding to 
sequences within exons 4 and 5, respectively. qPCT was also 
used to quantify expression of total D2-CD33 (forward, 
5'-CCCTGCTGTGGGCAGACTTG-3' (SEQ ID NO: 9); 
reverse, 5'-GCACCGAGGAGTGAGTAGTCC-3'(SEQ ID 
NO: 10)) primers corresponding to sequences at the exon 1-3 
junction and exon 3, respectively. The specificity of the 1 to 3 
junctional primer was confirmed by testing on CD33 
sequence fragments containing or lacking exon 2, as well as 
post-qPCR melting curve analysis and gel electrophoresis of 
PCR products. PCR was conducted using an initial 2 min 
incubation at 95°, followed by cycles of 10 sat 95°, 20s at 
60°, and 20s at 72°. The 20 ul reactions contained 1 uM each 
primer, 1X PerfecTa SYBR Green Super Mix (Quanta Bio 
sciences, Gaithersburg, Md.), and 20 ng of cDNA. Experi 
mental samples were amplified in parallel with serially 
diluted standards that were generated by PCR of cDNA using 
the indicated primers, followed by purification and quantita 
tion by UV absorbance. Results from samples were compared 
relative to the standard curve to calculate copy number in each 
sample. Real-time assays were performed twice, and the aver 
age copy number was used for additional data analyses. 
To evaluate the correlation between CD33 and that of 
microglial mRNAs, CD11b and AIF-1 expression was also 
quantified. The copy number for each mRNA was then nor 
malized to the geometric mean of reference genes RPL32 and 
EIF4H, previously quantified in this sample set. Because 
CD33 expression correlated with CD11b and AIF-1, total 
CD33 expression was compared to the geometric mean of 
CD11b and AIF-1 expression when analyzing CD33 expres 
sion relative to AD status and rs3865444 genotype, correcting 
for the microglial content of brain tissue samples from which 
the cDNA was originally prepared. Expression of D2-CD33 
was analyzed relative to total CD33 expression. To screen for 
CD33 SNPs that may be tightly linked to rs3865444 and 
modulate exon 2 splicing, seven individuals homozygous for 
the major or minor allele of rs3865444 were sequenced from 
400 bp 5' to the transcription start site through exon 4. Nested 
PCR was conducted according to the directions of the manu 
facturer (Phusion High-Fidelity DNA Polymerase: New 
England Biolabs, Ipswich, Mass.); 20 PCR cycles were con 
ducted with forward primer 5'-CTGTGCCCGAGCTGTCT 
TAT-3'(SEQID NO: 11) and reverse primer 5'-AGGCTCCT 
TCCTACCTGAGC-3' (SEQID NO: 12). PCR products were 
then diluted 1:25 and used in a second round of PCR (25 
cycles) using the forward primer 5'-GCTGCCACCT 
TCACTTTACC-3' (SEQ ID NO: 13) with reverse primer 
5'-TTGTTGGGTTCTGTGGAACA-3'(SEQ ID NO:14). 
The first round of PCR used about 80 ng of genomic DNA 
in a 20 ul reaction with both PCRs conducted using 3% 
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DMSO. This process identified four SNPs in this region: (1) 
rs3865444, the AD-associated promoter SNP; (2) rs2459 141, 
which is 142 bp upstream of the transcription start site; (3) 
rs 12459419 at the fourth base of exon 2; and (4) rs2455069 at 
the 168th base of exon 2. rS12459419 was linked with 
rs3865444 in these samples. Samples were subsequently 
genotyped for rs12459419 by using a TaqMan approach (In 
vitrogen); rs3865444 genotypes were determined by Ncol 
restriction fragment length polymorphism. 
CD33 minigenes containing exon 1 through exon 4 and 
differential for rs12459419C/T were generated by PCR and 
cloned into pcDNA3.1 (Invitrogen). Sequencing confirmed 
that the inserts differed only at rs12459419C/T. BV2 micro 
glial cells were maintained in DMEM/F-12 (Invitrogen) 
supplemented with a final concentration of 10% fetal bovine 
serum, 50 U/ml penicillin, and 50 lug/ml streptomycin. Cells 
were seeded in six-well plates (2x10 cells per well) and 
allowed to grow for 24 h before transfection with 1 lug of 
allele-specific CD33 minigene vector in 6 ul of Lipo 
fectamine 2000 reagent (Invitrogen) and 94 IA of Opti-MEM, 
per the recommendations of the manufacturer. Eighteenhours 
after transfection, poly(A+)RNA was prepared and reverse 
transcribed by using random hexamers per the directions of 
the manufacturer (SuperScript III; Invitrogen). Three trans 
fections were performed in duplicate for each allele. CD33 
and D2-CD33 expression from the minigene was quantified 
by qPCR using primers corresponding to exon 3-4 junction 
and 3' vector-derived sequence (5'CAGCTCAACGTCAC 
CTATGTTC (SEQ ID NO: 15) and 5'CGTAGAATC 
GAGACCGAGGA (SEQ ID NO: 16)) and 5' vector and the 
exon 1-3 junction (5"TGCTTACTGGCTTATCGAAATTA 
(SEQID NO:17) and 5'TGTGGGTCAAGTCTGCCC (SEQ 
ID NO: 18)), respectively. A one-tailed t test was used to 
analyze the results. 
Immunocytochemistry that localized CD33 expression in 
human brain showed that CD33 expression in microglia, as 
discerned by morphology (FIGS. 1A and 1B). Microglial 
localization was confirmed by double labeling brain sections 
for CD33 and IBA-1, a microglial protein, or GFAP, an astro 
cytic protein (FIGS. 1C to 1F). Overall, predominant micro 
glial localization is consistent with the potential role of CD33 
as a sialic acid receptor that inhibits monocyte-lineage cell 
activation. 
As discussed above, CD33 is encoded by seven exons, 
including the alternatively spliced exons 7A and 7B (see, e.g., 
FIG. 4). Common CD33 isoforms in human brain were found 
using PCR amplification on human brain cDNA using prim 
ers corresponding to exon 1 and exon 7A or 7B. Sequencing 
50 random clones revealed frequent isoforms lacking the 381 
bp exon 2 (D2-CD33). Because the codon reading frame is 
maintained in the absence of exon 2, D2-CD33 encodes a 
protein that is identical to CD33, but that lacks the IgV 
domain that mediates sialic acid binding in SIGLEC family 
members. Both D2-CD33 and CD33 were found on the cell 
surface of transfected cells. 
Without being bound by theory or mechanism, rs3865444 
modulates CD33 expression since this SNP is 372 bp 
upstream of the CD33 transcription start site. To analyze this 
finding. CD33 expression was assessed by performing qPCR 
with primers corresponding to sequence within exons 4 and 5. 
As described above, since immunostaining Suggested that 
CD33 localized primarily to microglia, CD33 expression was 
analyzed relative to the geometric mean of two microglial 
mRNAs, CD11b and AIF-1 (IBA-1), as well as AD status and 
rs3865444 genotype. It was observed that CD33 expression 
correlated strongly with microglial mRNA expression, was 
increased in AD, and was decreased with the AD-protective 
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rs3865444A allele (FIGS. 2A and 2B). Similarly, regression 
analysis showed a highly significant model (adjusted r°–0.76) 
wherein CD33 expression correlated significantly with 
microglial gene expression (p=3.3x10', standardized B 
coefficient of 0.78), AD status (p=5.9x10, standardized 0 
coefficient of 0.29), and rs3865444 genotype (p=0.012, stan 
dardized B coefficient of -0.17). These results are consistent 
with CD33 expression in microglia, increased CD33 expres 
sion in AD, and decreased CD33 expression with the protec 
tive rs3865444A allele. 
Because D2-CD33 was a common splice variant, 
D2-CD33 was quantified by performing qPCR with primers 
corresponding to the exon 1-3 junction and exon 3, as dis 
cussed above. D2-CD33 expression was compared with total 
CD33 expression, and isoform-specific standard curves were 
analyzed in parallel with samples, which allowed absolute 
quantitation of each isoform. D2-CD33 expression corre 
sponded with CD33 expression and with rs3865444 genotype 
(FIG. 2C). When D2-CD33 expression was considered as a 
percentage of total CD33 expression, the association with 
rs3865444 genotype was apparent (FIG. 2D). These findings 
were confirmed by linear regression analyses, which found a 
significant model (adjusted r=0.75) with D2-CD33 strongly 
associated with rs3865444 genotype (p=1.01x10', stan 
dardized f coefficient of 0.81), as well as CD33 expression (p=2.3x10', standardized B coefficient of 0.58), and 
decreased with AD status (p=0.013, standardized f coeffi 
cient of -0.19). Hence, the proportion of CD33 expressed as 
D2-CD33 showed a dose-dependent relationship with 
rs3865444 allele. Indeed, in this Example the percentage of 
CD33 expressed as D2-CD33 increased by 10.7+0.8% per 
copy of the AD-protective rs3865444A allele. 
Without being bound by theory or mechanism, since 
rs3865444 resides in the CD33 promoter, and is therefore 
unlikely to directly modulate exon 2 splicing, rs3865444 may 
be coinherited with an SNP near or within exon 2 that modu 
lates exon 2 splicing efficiency. To analyze this finding, CD33 
from 400 bp 5% of the transcription start site through exon 4 
was sequenced in four rs3865444C/C and three 
rs3865444A/A individuals, as described above. Four SNPs 
were observed in these samples: (1) rs3865444; (2) 
rs2459 141 (142 bp upstream of the transcription start site); 
(3) rs12459419 (the fourth base of exon 2); and (4) rs2455069 
(the 168th base of exon 2). Among these variations, only 
rs 12459419 was coinherited with rs3865444 in all seven indi 
viduals (i.e., rs3865444AA individuals were also 
rs 12459419TT), whereas rs3865444CC individuals were 
rs 12459419CC. Subsequent rs12459419 genotyping of the 
samples depicted in FIG. 2 found that rs12459419 major and 
minor alleles were coinherited with rs3865444 major and 
minor alleles. Thus, the rs12459419C/Talleles substitute for 
the rs3865444C/A alleles in FIG. 2. 
To evaluate whether rs12459419 is a functional polymor 
phism and directly modulates exon 2 splicing efficiency, 
CD33 minigenes for each rs12459419 allele were generated, 
as discussed above. These minigenes included exon 1 through 
exon 4, along with intervening introns, and the only differ 
ence in minigene sequences was the rs12459419 alleles. This 
analysis found that D2-CD33 as a percentage of total CD33 
increased approximately threefold between cells transfected 
with rs12459419C (3.4+1.4, mean+SE; n=3) versus 
rs 12459419T minigenes (10.3+2.3, meant-SE; n=3, 
p=0.034). These findings show that rs12459419 is a func 
tional polymorphism and are consistent with the human brain 
findings. In silico analysis of RNA binding proteins for the 
RNA sequence containing rs12459419, GGG (C/U)CUG. 
predicts that the splicing factor SRSF2 binds when 
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rs 12459419C is present but not when rs124594149U is 
present (scores of 4.1 and 1.4, respectively, threshold score 
for binding of 2.4). SRSF2 is widely expressed, including 
immune cells. It thus appears that rs12459419 mediates the 
rs3865444 association with D2-CD33 expression in brain 
becausers 12459419 is highly coinherited with rs3865444, is 
the only SNP in exons 1-4 that is coinherited with rs3865444, 
resides within exon 2, and has a plausible mechanism to 
modulate splicing. 
In summary, CD33 expression is increased in AD and in 
individuals with the rs3865444Callele that is associated with 
increased AD risk. Moreover, rs3865444 is associated with 
CD33 exon 2 splicing efficiency through the exon 2 polymor 
phism rs12459419, and rs12459419 may also be an appropri 
ate polymorphism for developing AD treatments. 
Example 2 
This Example extends to the findings of Example 1, and 
shows that Int1-CD33 is also correlated with rS444. This 
result steps from the fact that, as shown in Example 1, exon 2 
splicing correlates with rS444 genotype. 
Using the same methods and materials described in rela 
tion to Example 1, an Int1-CD33 specific qPCR assay was 
generated (FIG. 5). As shown in FIG. 5, Int1-CD33 expres 
sion correlated with total CD33 expression (FIG. 5A, 
adjusted R=0.20) and with rs444 genotype (FIG. 5B, 
p=0.004). The percentage of CD33 expressed as Int1-CD33 
showed a dose-dependent relationship with rS444 allele, 
increasing 2.3+0.8% per rS444A allele. Since D2-CD33 lacks 
the ligand binding domain and Int1-CD33 has an early stop 
codon, the amounts of D2-CD33 and Int1-CD33 were 
summed as “Non-functional CD33’ to estimate the total 
effect of rS444. 
Non-functional CD33 was significantly associated with 
rs444 (p=1x10') in a robust linear model (adjusted 
R=0.657) (FIGS. 5C and 5D), with the percentage of CD33 
expressed as non-functional-CD33 increasing 13.8+1.9% per 
copy of AD-protectivers444A allele. It thus appears that there 
was a significant 13.8% increase per protectivers444A allele 
in CD33 encoding non-functional CD33 protein. Since 
rs444A reduces the AD odds ratio to 0.9, more robust CD33 
inhibition may reduce AD more robustly. For example, a six 
times stronger (i.e., about 84%) CD33 inhibition may reduce 
AD odds ratio to 0.4. 
While the terms used herein are believed to be well under 
stood by one of ordinary skill in the art, definitions are set 
forth herein to facilitate explanation of the presently-dis 
closed subject matter. 
Unless defined otherwise, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the presently 
disclosed subject matter belongs. Although any methods, 
devices, and materials similar or equivalent to those described 
herein can be used in the practice or testing of the presently 
disclosed subject matter, representative methods, devices, 
and materials are now described. 
Following long-standing patent law convention, the terms 
“a”, “an', and “the refer to “one or more' when used in this 
application, including the claims. Thus, for example, refer 
ence to “an antibody' includes a plurality of such antibodies, 
and so forth. 
Unless otherwise indicated, all numbers expressing quan 
tities of ingredients, properties such as reaction conditions, 
and so forth used in the specification and claims are to be 
understood as being modified in all instances by the term 
"about'. Accordingly, unless indicated to the contrary, the 
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numerical parameters set forthin this specification and claims 
are approximations that can vary depending upon the desired 
properties sought to be obtained by the presently-disclosed 
Subject matter. 
As used herein, the term “about, when referring to a value 
or to an amount of mass, weight, time, Volume, concentration 
or percentage is meant to encompass variations of in some 
embodiments +20%, in some embodiments +10%, in some 
embodiments +5%, in some embodiments +1%, in some 
embodiments +0.5%, and in some embodiments +0.1% from 
the specified amount, as Such variations are appropriate to 
perform the disclosed method. 
As used herein, ranges can be expressed as from “about 
one particular value, and/or to “about another particular 
value. It is also understood that there are a number of values 
disclosed herein, and that each value is also herein disclosed 
as “about that particular value in addition to the value itself. 
For example, if the value “10 is disclosed, then “about 10” is 
also disclosed. It is also understood that each unit between 
two particular units are also disclosed. For example, if 10 and 
15 are disclosed, then 11, 12, 13, and 14 are also disclosed. 
The presently-disclosed subject matter is further illustrated 
by the following specific but non-limiting examples. The 
following examples may include compilations of data that are 
representative of data gathered at various times during the 
course of development and experimentation related to the 
present invention. 
Throughout this document, various references are men 
tioned. All such references are incorporated herein by refer 
ence, including the references set forth in the following list: 
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It will be understood that various details of the presently 
disclosed subject matter can be changed without departing 
from the scope of the subject matter disclosed herein. Fur 
thermore, the foregoing description is for the purpose of 
illustration only, and not for the purpose of limitation. 
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22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 1 
citcaga catg cc.gctgct 
<210s, SEQ ID NO 2 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 2 
ttcaatggcc atcatctoct 
<210s, SEQ ID NO 3 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 3 
catcc catga aagttgaggg 
<210s, SEQ ID NO 4 
&211s LENGTH: 18 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
& 22 O FEATURE; 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 4 
tactgctgcc cct gctgt 
<210s, SEQ ID NO 5 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 5 
tggc catcat citcctgat ct 
<210s, SEQ ID NO 6 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 6 
aatgcagotc ct catc catc 
<210s, SEQ ID NO 7 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OO > SEQUENCE: 7 
tgttccacag aacccaacaa 
US 9,066,928 B1 
- Continued 
18 
18 
20 
21 
<210s, SEQ ID NO 8 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 8 
ggctgtaa.ca cca.gct cotc 
<210s, SEQ ID NO 9 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 9 
CCCtgctgtg ggcagacittg 
<210s, SEQ ID NO 10 
&211s LENGTH: 21 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 10 
gCaccgagga gtgagtag to c 
<210 SEQ ID NO 11 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 11 
ctgtgc.ccga gctgtctitat 
<210s, SEQ ID NO 12 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 12 
aggctic ctitc ctacctgagc 
<210s, SEQ ID NO 13 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 13 
gctgccacct tcactttacc 
<210s, SEQ ID NO 14 
&211s LENGTH: 2O 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
223s OTHER INFORMATION: Primer 
US 9,066,928 B1 
- Continued 
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22 
US 9,066,928 B1 
23 24 
- Continued 
<4 OOs, SEQUENCE: 14 
ttgttgggitt Ctgtggaa.ca 
SEO ID NO 15 
LENGTH: 22 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Primer 
< 4 OOs SEQUENCE: 15 
cagotcaacg to acctatgt to 
SEQ ID NO 16 
LENGTH: 2O 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Primer 
16 <4 OOs, SEQUENCE: 
cgtagaatcg agaccgagga 
SEO ID NO 17 
LENGTH: 23 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Primer 
< 4 OO SEQUENCE: 17 
tgct tactgg cittatcgaaa tta 
SEQ ID NO 18 
LENGTH: 18 
TYPE: DNA 
ORGANISM: Artificial Sequence 
FEATURE: 
OTHER INFORMATION: Primer 
<4 OOs, SEQUENCE: 18 
tgtgggtcaa gtctgc cc 
What is claimed is: 
1. A method of treating Alzheimer's disease in a Subject, 
comprising: 
administering a CD33 antibody to the subject, the subject 
being identified as having a single nucleotide polymor 
phism (SNP) selected from rs3865444, rs12459419, and 
combinations thereof. 
2. The method of claim 1, wherein the CD33 antibody 
includes lintuzumab, P67.6, or combinations thereof. 
3. The method of claim 1, further comprising administer 
ing to the Subject at least one additional component useful for 
treating Alzheimer's disease. 
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4. The method of claim 3, wherein the at least one addi 
tional component useful for treating Alzheimer's disease is 
selected from galantamine, rivastigmine, donepezil, tacrine, 
memantine, Vitamin E, and combinations thereof. 
5. The method of claim 1, wherein the subject is not being 
treated for a cancer. 
6. The method of claim 1, wherein the subject does not have 
acute myeloid leukemia (AML) and/or has not been identified 
as being at risk for developing AML. 
k k k k k 
